Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

 
 
BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Alzheimer's Disease Research
Current Award

Dr. Tae-Wan Kim

Tae-Wan Kim, Ph.D.

Columbia University Medical Center
New York , NY, United States

Title: Novel CNS Transporter Target in Alzheimer's Disease
Non-Technical Title: Novel Drug Target for Alzheimer's Disease

Duration: July 1, 2012 - June 30, 2014
Award Type: Standard
Award Amount: $150,000

Summary:

Dr. Tae-Wan Kim and colleagues have identified an ‘atypical monoamine transporter’ as a novel therapeutic target in Alzheimer's disease. The proposed research is designed to further validate the new target and generate therapeutic lead compounds. Further research will be conducted to understand this target in greater depth, using cell biological approaches.

Details:

Alzheimer's disease (AD) is characterized pathologically in the brain by the accumulation and deposition of amyloid beta-peptide (Abeta), a small protein with a high propensity for aggregation and neuro-toxic effects. The production of Abeta is controlled by the cleavage of amyloid precursor protein (APP) by two enzymes, beta-secretase (BACE1) and gamma-secretase. A major focus of drug development for AD has been to inhibit these enzymes directly, in order to preclude the liberation of Abeta from APP. However, major late-stage clinical trials have been disappointing due to lack of efficacy or side effects of these drugs in humans.

Since directly targeting BACE1 and gamma-secretase has proven largely ineffective, new molecular targets must be identified that can reduce brain Abeta levels through alternate pathways. In order to identify novel pathways for disruption of Abeta production, Dr. Tae-Wan Kim’s team has developed a novel screening strategy using intact neuronal cells harboring a fluorescent reporter of BACE1 cleavage of APP. This approach allows identification of completely new pathways for regulating Abeta production. Using this strategy, they identified multiple small-molecule chemical compounds that reduced APP cleavage in intact cells but did not inhibit BACE1 directly. This approach allows the identification of a completely new pathway for regulating Abeta production. The cellular target of this lead compound has not yet been identified, and this information is critical to fully exploit the newly discovered cellular pathway for regulation of Abeta production. 

The goal of this study is to identify the cellular target of this new small molecule. Based on preliminary data, the research team hypothesizes that the target is a member of a class of neurotransmitter transporters. This is a highly “drug-able” class of transporters that has previously been targeted in treatments for depression and drug addiction, but not yet explored for AD. Dr. Kim’s team will determine if the compound binds directly to the putative target transporter, critical data for future drug development, as well as determine the molecular and cellular pathways harnessed by this new compound for Abeta reduction.

Since this newly identified compound targets a novel cellular pathway in neurons known to be vulnerable in AD, completion of these studies will lay the groundwork for future development of this lead compound into a drug candidate. This study will also introduce the field to a completely novel cellular mechanism for critically lowering Abeta production and explore a new strategy for developing AD therapeutics.

Investigator Biography:

Tae-Wan Kim obtained his undergraduate degree from Yonsei University, Seoul, Korea, and received his Ph.D. in neurobiology under the supervision of the late I. B. Black from Rutgers University, New Jersey. Following postdoctoral training with R. E. Tanzi at the Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, Kim held faculty appointments at Harvard Medical School and Columbia University. He is currently an associate professor in the Department of Pathology and Cell Biology and in the Taub Institute at Columbia University. His research is focused on understanding the genetic and epigenetic mechanism of Alzheimer's disease with emphasis on the identification and validation of new therapeutic targets, including phospholipid-modifying enzymes. Kim received the 2000 Ruth Salta Junior Investigator Achievement Award from the American Health Assistance Foundation.